Here we demonstrate that AIDS-KS cells express surface interleukin-4 (IL-4) receptors, and that IL-4 toxin (IL-4(38-37)-PE38KDEL) is specifically cytotoxic to these cells. Intratumoral ...

We tested the ability of intraperitoneal (i.p.) injection of Ad5mIL-4 to yield detectable levels of serum mIL-4 production in female NOD mice. IL-4 (1.0–2.0 ng/ml) was transiently expressed in ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

koto.kpu-m.ac.jp Aim To investigate the expression and function of interleukin-4 receptor α (IL-4Rα) in human conjunctival epithelial cells (HCjECs). Methods The presence of IL-4Rα mRNA and protein ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with ...

mondino.it Intracellular cytokine flow cytometry was used to analyse the percentages of interferon (IFN) γ and interleukin (IL)-4 producing T cells in the peripheral blood of multiple sclerosis ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Over the years, companies have explored interleukin as treatments for cancer, autoimmune conditions, and inflammatory diseases. But while some interleukin-based drugs have reached the market, many ...

Regeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).